Delivery Order SPE2DR25D3111-SPE2DR26FF4DA
- Not listed
- AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, was awarded a delivery order valued at $27,762.71 for Vivitrol 380 mg vial-diluents on August 14, 2025. This competitively awarded, firm fixed-price contract carries an ultimate completion date of August 15, 2025 and serves the Defense Logistics Agency's Medical Supply Chain. The award represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a...
- AmerisourceBergen Drug Corp was awarded a delivery order by the Defense Logistics Agency (DLA) on August 13, 2025, for the supply of Vivitrol 380 mg vials with diluents. This is a firm fixed-price delivery order with a ceiling value of $6,007.02 and an ultimate completion date of August 14, 2025. The contract carries no set-aside designation, indicating it was competitively awarded through open competition. The place of performance is AmerisourceBergen's corporate office location in...
- AmerisourceBergen Drug Corp has been awarded a delivery order valued at $9,413.20 by the Defense Logistics Agency for VIVITROL 380 mg vials with diluents. The award is structured as a firm fixed price delivery order with an ultimate completion date of July 1, 2025, and was competitively awarded without set-aside provisions. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, will perform work at its corporate office location. This delivery order represents a child contract under...
- AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, was awarded a delivery order valued at $2,379.06 on January 9, 2026, for the supply of Vivitrol 380 mg vial-diluents. The contract, which represents a firm fixed-price transaction with an ultimate completion date of January 12, 2026, was competitively awarded with no set-aside designation. This delivery order is issued under AmerisourceBergen's parent company Cencora, Inc.'s larger...
- Amerisourcebergen Drug Corp, a subsidiary of Cencora, Inc., received a delivery order award from the Defense Logistics Agency (DLA) on January 26, 2026, for the supply of Vivitrol 380 mg vial-diluents. This firm fixed-price delivery order, valued at $15,144.49, is unscheduled for completion by January 27, 2026, and carries no set-aside designation, indicating it was competitively awarded. The place of performance is the company's corporate office location in Conshohocken, Pennsylvania. This...
- The Defense Logistics Agency awarded a $11,091.90 delivery order to AmerisourceBergen Drug Corp on January 21, 2026, for the supply of Vivitrol 380 mg vial-diluents. The award is non-competitive and structured as a firm fixed-price delivery order under a larger indefinite delivery contract vehicle. The product will be delivered to AmerisourceBergen's corporate headquarters location in Conshohocken, Pennsylvania, with an ultimate completion date of January 22, 2026. AmerisourceBergen Drug Corp is...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $1,116.03 for Vivitrol 380 mg vial-diluents, with an ultimate completion date of December 15, 2025. This is a firm fixed price delivery order with no set-aside designation, competitively awarded to the pharmaceutical distributor's Corporate Office located in Conshohocken, Pennsylvania. The award represents a child contract action under AmerisourceBergen's larger Indefinite Delivery Contract vehicle with...
- The Defense Logistics Agency awarded a delivery order valued at $4,436.76 to AmerisourceBergen Drug Corp for the supply of Vivitrol 380 mg vials and diluents, with an ultimate completion date of February 4, 2026. This is a firm fixed-price, non-set-aside contract with performance in Conshohocken, Pennsylvania. The award represents a task order under AmerisourceBergen's parent company Cencora, Inc.'s larger Indefinite Delivery Contract with DLA Troop Support Medical, a single-award IDC valued...
- The Defense Logistics Agency awarded a $4,876.18 delivery order to AmerisourceBergen Drug Corp for Vivitrol 380 mg vial-diluents, with an ultimate completion date of January 23, 2026. This competitively awarded, firm fixed-price contract represents a non-set-aside procurement to be performed at the company's corporate office location in Conshohocken, Pennsylvania. The award is a child order under AmerisourceBergen's larger pharmaceutical supply framework with the DLA. AmerisourceBergen Drug...
- The Defense Logistics Agency awarded a $4,569.98 delivery order to AmerisourceBergen Drug Corp for Vivitrol 380 mg vials with diluents on January 14, 2026, with completion targeted for January 15, 2026. This firm fixed-price contract represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical. The contract was competitively awarded with no set-aside designation and will be fulfilled from the contractor's facility in Conshohocken,...
- SPE2DR25D3111Indefinite Delivery Contract
- SPE2DR25D3111-SPE2DR26FF4DADelivery Order
AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, was awarded a delivery order by the Defense Logistics Agency on February 3, 2026, for the supply of Vivitrol 380 mg vial-diluents. This competitive, firm fixed-price delivery order carries a ceiling value of $1,109.19 and is scheduled for ultimate completion by February 4, 2026. The award was issued under the company's parent organization Cencora, Inc., which holds a significant Indefinite Delivery Contract with DLA Troop Support Medical valued at up to $999,999,999.00 through December 31, 2031. This prime IDC serves as a comprehensive global pharmaceutical support vehicle enabling the delivery of prescription medications, vaccines, medical supplies, and other critical healthcare commodities to support military healthcare programs worldwide. The delivery order reflects AmerisourceBergen's established role as a critical vendor within the federal medical procurement supply chain. Vivitrol (naltrexone extended-release injection) is an FDA-approved medication used in the treatment of opioid use disorder and alcohol dependence, making this procurement consistent with the Department of Defense's broader healthcare mission. The company's federal contract portfolio demonstrates extensive experience fulfilling comparable pharmaceutical orders for the Defense Health Agency and other military healthcare systems. No set-aside designation was applied to this award, indicating it was competitively awarded on a full and open basis.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $1.1k | 2/2/26 |